Aegis Therapeutics says that it has developed an intranasal hydromorphone for the treatment of acute pain and is making the formulation available for license. According to the company, the formulation, which is based on the Intravail absorption enhancement technology, has demonstrated rapid onset and a Tmax of 7.5 minutes.
A patent application filed by Aegis in 2013 and titled “Compositions for drug administration”, which says that the “invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject,” includes hydromorphone as one of numerous opioids that could be used with the bioavailability enhancement technology.
Read the Aegis Therapeutics press release.
